OBJECTIVES: This study aimed to determine anti-coagulant treatment patterns and stroke- and bleeding-related risk factors and to evaluate quality of life (QoL) in non-valvular atrial fibrillation (NVAF) patients. METHODS: This multicenter (12-centers), observational study included ≥18 year-old patients (n=213) diagnosed with NVAF. CHADS, CHADS-VASc, HAS-BLED scores and EQ-5D scale were used to assess risk factors and QoL and clinical features were recorded at baseline, and 6^th and 12^th months. RESULTS: The rate of adverse events was 64.7%, major bleeding was 10.8%, stroke was 5.9%, and hospitalization was 25.5% in one-year follow-up. The patients’ treatment patterns were grouped as warfarin, new oral anti-coagulant (NOAC) (dabigatran, rivaroxaban), and antiplatelet agents (AA) (acetylsalicylic acid, clopidogrel). Patient numbers for the groups at baseline, and 6^th and 12^th months, respectively, were 92, 74, 41 for warfarin, 2, 13, 14 for NOAC, and 39, 29, 26 for AA. The distribution of patients in the warfarin, NOAC, and AA groups regarding CHADS≥2 was 53.8% (n=49), 50% (n=1), and 63.2% (n=24), respectively; regarding CHADS-VASc≥2 was 86.8% (n=79), 50% (n=1), and 89.5% (n=34), respectively; and regarding HAS-BLED≥3 (high bleeding risk) was 23.1% (n=21), 0% (n=0), and 18.4% (n=7), respectively. EQ-5D scale scores were 0.85±0.12 and 0.76±0.13 at baseline and 0.67±0.29 and 0.62±0.37 at 12^th month for the warfarin and AA groups, respectively; the decrease was significant in the warfarin group (p=0.002) but not in the AA group (p=0.249). The mortality rates of the patients in the warfarin, NOAC, and AA groups in one-year follow-up were 7.6%, 0.0%, and 10.3%, respectively. CONCLUSIONS: Our study has demonstrated that a significant number of patients who should be on oral anticoagulants are still treated with AA and the negative effects of warfarin on QoL of NVAF patients as compared to AA. More data is needed with head-to-head comparison of warfarin and NOAC.